Residual ASCVD Risk (TG) — EECC MCQ

Instant feedback + full explanation. One question, done properly.

ModerateCardiologyResidual ASCVD Risk (TG)EECC

A 70-year-old with T2D and established ASCVD has LDL 1.8 mmol/L on high-intensity statin and ezetimibe. Triglycerides 2.0 mmol/L. What next to reduce events?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Add icosapent ethyl

In patients with controlled LDL and elevated triglycerides (1.5-5.6 mmol/L) on statins, icosapent ethyl reduces CV events. Fibrates/niacin lack consistent event reduction; PCSK9 targets LDL, which is already at goal.

Reference: ACC Expert Consensus Decision Pathway (2022): Nonstatin Therapies